43rd week of 2021 patent applcation highlights part 10 |
Patent application number | Title | Published |
20210330724 | CANNABIDIOL ALKALINE COMPOSITION - An aqueous alkaline composition comprising a cannabinoid which may be cannabidiol (CBD) used alone or in combination with other cannabinoids. An alkalizing agent which comprises pico size carbon particles is present in the composition, in an amount suitable for buffering the composition to a pH between about 7.5 and 9.5. The aqueous alkaline composition is stable and may be used in the preparation of a beverage or a pharmaceutical composition. | 2021-10-28 |
20210330725 | GARCINIA MANGOSTANA EXTRACT FOR PROMOTING HAIR GROWTH - The present invention relates to a | 2021-10-28 |
20210330726 | Dietary herbal health supplement for the management and treatment of Parkinson's disease - A dietary herbal health supplement to reduce the symptoms of Parkinson's disease in a human subject comprising orally administering to a subject in need thereof an effective amount of the supplement comprising | 2021-10-28 |
20210330727 | PLANT EXTRACT OBTAINED FROM MORUS PLANT LEAVES, COMPOSITIONS CONTAINING SAME, METHOD OF EXTRACTION AND USES THEREOF - An extract from leaves of mulberry is disclosed. The extract has an IC50 value sufficient to inhibit a-glucosidase I. The extract may comprise 5-40%(w/w) total imino sugars and 20-70% (w/w) total amino acids. The extract may reduce the production of melanin for the treatment of such ailments or diseases caused by pigmentation as freckle, chloasma, striae gravidarum, sensile plaque and melanoma. The extract may also control blood glucose level. | 2021-10-28 |
20210330728 | Methods of Clinical Treatment of a Mammal Experiencing a Viral Respiratory Infection and/or Inflammation Resulting from a Viral Respiratory Infection Using Botanical Infusion - As described herein, the invention includes methods for the treatment of a respiratory infection of a coronavirus and/or respiratory inflammation resulting from a coronavirus infection in a mammalian individual. The method includes administering to the individual an effective amount of a water-based infusion prepared by steeping the leaves of eucalyptus globulus Labill, the root of astragalus membranaceus, and the leaves of mentha X piperita in a liquid for a time duration and administering to the patient an effective amount of the infusion. Such administration may be via an oral or an inhalable route. Also included are methods of making a composition for use in the clinical treatment of a COVID-19 (SARS-CoV-2) infection and/or to treat inflammation resulting from an is COVID-19 (SARS-CoV-2) infection comprising steeping in a liquid leaves of eucalyptus globulus Labill, roots of astragalus membranaceus, and the leaves of mentha X piperita, for a duration of time. | 2021-10-28 |
20210330729 | DIETARY FIBER COMPOSITIONS - The present disclosure relates to compositions comprising dietary fibers. For example, in some embodiments, the composition comprises two or more fibers (e.g., fibers such as wheat dextrin, inulin, pectin, or potato starch) each present in amount of about 2% to about 6% w/w of the composition. The present disclosure also relates to partially hydrolyzed dietary fibers and methods to prepare a partially hydrolyzed dietary. In some embodiments, the composition comprises further comprises an acid and/or a preservative present in an amount of about 0.01% to about 2% w/w of the composition. In some embodiments, the composition further includes a sweetener and/or a flavoring agent. Such compositions are useful in the treatment or improvement of gastrointestinal diseases. | 2021-10-28 |
20210330730 | Traditional Chinese Medicine Composition For Treating Type 2 Diabetes - The application discloses a traditional Chinese medicine composition for treating of type 2 diabetes, comprising the following raw materials: wild Descolor Cinquefoil Herb, wild Rhizoma imperatae, wild Root and Rhizome of Japanese Climbing Fern, Ginseng leaf (over 7 years), wild Rough Melic, wild | 2021-10-28 |
20210330731 | TOPICAL SALVE FORMULATIONS FOR DERMAL ALKALOID DELIVERY - Various formulations of an alkaloid-containing topical analgesic involve extracting alkaloids from herbal material, infusing a carrier oil, and applying secondary ingredients to improve the formulation's therapeutic efficacy. Suitable herbal sources include, but are not limited to, Mitragyna speciosa, Rauwolfia serpentina, Sceletium tortuosum, Harpagophytum procumbens, Picralima natilda, Sceletium tortuosum, Combretum quadrangulare, Corydalis yanhusuo, Lactuca virosa, and/or Magnolia officinalis. Preferably, alcohol extractions of pre-frozen herbal material were vacuum reduced and the resulting alkaloid extraction was infused into an oil and combined with secondary ingredients, such as alkaloid potentiators, dermal absorption enhancers, anti-inflammation agents, brightening agents, neuropathic pain relief agents, and spasm relief agents. | 2021-10-28 |
20210330732 | METHOD OF MAKING SOLANACEAE FRUIT EXTRACTS - Provided are methods of making an extract of fruit of the Solanaceae family wherein fruit is processed to optimise the platelet aggregation inhibiting activity of the extract. The methods involve preparing a start mix of homogenised fruit; separating a water soluble fraction from fruit solids; filtration of the water soluble fraction; and concentration of active agents in the filtration permeate. The invention also provides fruit extracts manufactured by such methods, and also fruit extracts containing glycosylated phenolic acid or a phenolic ester, or derivatives thereof; a glycosylated flavonoid; and a nucleoside. The extracts of the invention are useful as medicaments for the treatment or prevention of a medical condition characterised by inappropriate platelet aggregation. In particular, the medicaments may be of use in maintaining heart health by reducing platelet aggregation; benefiting the circulation; and/or normalizing or otherwise benefiting blood flow. | 2021-10-28 |
20210330733 | TOPICAL COMPOSITION FOR PAIN RELIEF - A topical composition for nociceptive and neuropathic pain relief comprising one or more of menthol, camphor, methyl sulfonyl methane, lidocaine, | 2021-10-28 |
20210330734 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES - Compositions including small molecule biochemicals, and salts and derivatives thereof, and methods for detection, treatment or prophylaxis of neurodegenerative diseases are provided, including compositions and methods for detecting and treating conditions that contribute to neurodegenerative diseases, including peripheral and central inflammation, amyloid-β plaque deposition in the brain, neuronal iron deposition and hyperglycemia. | 2021-10-28 |
20210330735 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TRAUMATIC OPTIC NEUROPATHY - The present disclosure provides novel methods for treating or preventing traumatic optic neuropathy (TON), methods for improving visual function in a subject having TON, methods for promoting retinal ganglion cell (RGC) survival or increasing neurite outgrowth of an RGC, and methods for reducing the risk of having or developing TON in a subject that has experienced a traumatic injury. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide. | 2021-10-28 |
20210330736 | USE OF A PDE11 OR PDE2 INHIBITOR FOR THE TREATMENT OF PARKINSON'S DISEASE - In embodiments the invention relates to means and methods for the treatment of Parkinson's disease. In some embodiments the means and methods involve a PDE2 inhibitor, a PDE11 inhibitor or a combination thereof, optionally together with a GUCY2C agonist. | 2021-10-28 |
20210330737 | Treatment of Rhinosinusitis with P-glycoprotein Inhibitors - Provided herein are, inter alia, methods for treating rhinosinusitis with P-glycoprotein inhibitors. A subject having rhinosinusitis is identified and then treated by administration to the subject an effective amount of a P-gp inhibitor. The subject having rhinosinusitis can be identified by one of skill in the art based on known methods, e.g., based on detection of the presence of symptoms, by endoscopy, or by computed tomography. The efficacy of the treatment can be monitored by methods known in the art, e.g., by monitoring symptoms, by endoscopy or computed tomography. The P-glycoprotein inhibitor can be delivered to the subject's nasal passage and sinuses by an inhalation device, by flushing, by spraying, or by an eluting implant surgically placed in the subject's nasal passage or sinuses. The P-glycoprotein inhibitor can also be administered in combination with one or both of a corticosteroid and an antibiotic. | 2021-10-28 |
20210330738 | ANTIMICROBIAL, BACTERIOPHAGE-DERIVED POLYPEPTIDES AND THEIR USE AGAINST GRAM-NEGATIVE BACTERIA - Disclosed herein are pharmaceutical compositions comprising an effective amount of an isolated Chp peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs. 1-4, 6-26 and 54-66, or a modified Chp peptide having about 80% sequence identity therewith, wherein the modified Chp peptide inhibits growth, reduces the population, or kills at least one species of Gram-negative bacteria; and a pharmaceutically acceptable carrier. Further disclosed herein are isolated Chp peptides, as well as vectors comprising a nucleic acid molecule that encode the Chp peptides and host cells comprising a vector. Also disclosed herein are methods of inhibiting the growth, reducing the population, or killing of at least one species of Gram-negative bacteria and methods of treating a bacterial infection in a subject. | 2021-10-28 |
20210330739 | PRODUCTS AND METHODS USING LUNASIN-ENRICHED SOY EXTRACT MIXTURES TO REDUCE FREE FATTY ACID LEVELS, INCREASE LEPTIN LEVELS AND INCREASE ADIPONECTIN LEVELS IN PLASMA - This invention relates generally to products and methods using lunasin-enriched soy extract combined with Reliv Now® to reduce free fatty acid levels and increase leptin levels and adiponectin levels in plasma for the control of obesity, type 2 diabetes and metabolic syndrome. More specifically, the present invention relates to novel compositions comprising lunasin enriched soy extract and Reliv Now® formulations, methods of using these compositions in individuals for the control of obesity, type 2 diabetes and metabolic syndrome, and methods of making compositions comprising them. | 2021-10-28 |
20210330740 | RUNX3 MODIFIED PROTEIN FOR PREVENTION OR TREATMENT OF CANCER - In the present invention, it was confirmed that the modified protein in which the 356 | 2021-10-28 |
20210330741 | POLYPEPTIDE THERAPEUTICS AND USES THEREOF - Methods and composition for delivery of enzymes to a subject's airway. In some aspects, nebulized composition of enzymes, such as plasminogen activators are provided. In further aspects perfluorocarbon compositions comprising enzymes, such as plasminogen activators are provided. Compositions may, in some aspects, be used for the treatment of lung infections or acute lung injury, such as inhalational smoke induced acute lung injury (ISALI). | 2021-10-28 |
20210330742 | PHARMACEUTICAL COMPOSITION COMPRISING RUNX3 PROTEIN AND CDK4 INHIBITOR OR mTOR INHIBITOR COTREATMENT FOR PREVENTION OR TREATMENT OF CANCER - The present invention relates to a pharmaceutical composition for prevention or treatment of cancer, comprising a Runx3 (Runt-related transcription factor 3) protein, a polynucleotide encoding thereof, a vector carrying the polynucleotide or a virus or cell transformed with the vector; and a CDK4 inhibitor or an mTOR inhibitor as an active ingredient. It was confirmed that the binding of Runx3 and BRD2 was maintained for up to 8 hours when the CDK4 inhibitor (PD0332991) was present at the concentration of 11 nM known to be non-toxic to normal cells. It was also confirmed that the binding of Runx3 and BRD2 was maintained for up to 8 hours when the mTOR inhibitor (rapamycin) was present at the concentration of 100 nM known to be non-cytotoxic to normal cells. In addition, it was confirmed that the cancer apoptotic effect was significantly increased when the CDK4 inhibitor or mTOR inhibitor was administered simultaneously with Runx3 than when Runx3 was administered alone to Runx3 deficient cancer cells. Therefore, the CDK4 inhibitor or mTOR inhibitor can be effectively used for preventing or treating various cancers by administering the same in combination with Runx3. | 2021-10-28 |
20210330743 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER - A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin. | 2021-10-28 |
20210330744 | Methods and Compositions for Treating Neurodegeneration and Fibrosis - This invention is generally related to novel compositions and methods for treating or preventing fibrosis, diseases or disorders associated with fibrosis, neurodegeneration, diseases or disorders associated with neurodegeneration and cardiovascular disease or disorders. | 2021-10-28 |
20210330745 | MODULATING RENAL LYMPHATICS TO REGULATE BLOOD PRESSURE - The present invention relates to a method for reducing blood pressure by stimulating lymphatic vessel growth and/or lymphangiogenesis in the kidneys. | 2021-10-28 |
20210330746 | COMPOSITIONS AND METHODS TO MITIGATE OR PREVENT AN IMMUNE RESPONSE TO AN IMMUNOGENIC THERAPEUTIC MOLECULE IN NON-HUMAN PRIMATES - Methods and compositions for preventing an immune response to an immunogenic therapeutic agent [i.e. anti-drug antibody (ADA), a.k.a. anti-therapeutic antibody (ATA)] are disclosed. One of the disclosed methods comprises administering an effective amount of an immunosuppressant such as an IL-2 signaling pathway inhibitor, including an antagonist, super agonist or partial agonist to the cytokine IL-2, to the IL-2 receptor (IL-2R), or to IL-2R signal transduction molecules. Inhibitors can be in the form of antibodies or antibody fragments, peptide inhibitors, fusion molecule, small molecules, antibody/small molecule conjugates. Administration of a given inhibitor can decrease the incidence and/or magnitude of an immune response or prevent an immune response, including an antibody response, to a potentially immunogenic therapeutic agent in a non-human primate (NHP). Some of the disclosed methods produce a tolerizing effect in NHPs. | 2021-10-28 |
20210330747 | Pharmaceutical Compositions and Pharmaceutical Products of Heterodimeric Human Interleukin-15 (hetIL-15) - The disclosure is directed to stable pharmaceutical compositions comprising a heterodimer complex of IL-15 and IL-15Rα and pharmaceutical products comprising such compositions. The disclosure is also directed to the use of these compositions (e.g. as part of a kit having instructions for use) and pharmaceutical products for the treatment of lymphopenia, cancer, or infectious disease. | 2021-10-28 |
20210330748 | SEMAGLUTIDE FOR USE IN MEDICINE - The present invention is directed to use of the GLP-1 receptor agonist semaglutide in medical therapy for the treatment of non-alcoholic steatohepatitis. | 2021-10-28 |
20210330749 | GLUCAGON ANALOGUES AS LONG-ACTING GLP-1/GLUCAGON RECEPTOR AGONISTS IN THE TREATMENT OF FATTY LIVER DISEASE AND STEATOHEPATITIS - The present invention relates to the medical use of specific long-acting glucagon analogues having dual GLP-1/glucagon receptor agonist activity in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), NAFLD-associated liver fibrosis and/or cirrhosis. | 2021-10-28 |
20210330750 | LACTATE-PROTECTED HYPOGLYCEMIA TO TREAT GLYCOLYSIS DEPENDENT PATHOLOGICAL CONDITIONS, IN PARTICULAR CANCER - A kit includes the components lactic acid, insulin and glucose, and optionally one or more components selected from a glucagon inhibitor, an alpha-beta adrenergic blocker and an antidiabetic agent, for treating a glycolysis-dependent pathological condition in a human or animal. A treatment includes intravascular, in particular intravenous, delivery of the components lactic acid, insulin and glucose into the circulation of the human or animal to be treated to induce hypoglycemia and hyperlactatemia. The glycolysis-dependent pathological condition is selected from the group consisting of cancer, bacterial infection or parasite infection. | 2021-10-28 |
20210330751 | Insulins Compatible with New Generation Implantable Pumps - A closed device for introducing preservative-free insulin into the intraperitoneal space is presented. In embodiments, the closed device includes an insulin reservoir configured to store preservative-free insulin, a pump connected to the reservoir, and an antimicrobial inlet filter connected to an inlet of the reservoir or provided in an inlet flow path in fluid communication with the reservoir. The device is configured to be disposed in the intraperitoneal space of a body, and to discharge preservative-free insulin into a peritoneal space of the body. In some embodiments, the device includes a second antimicrobial filter, provided at an outlet of the reservoir. In some embodiments, the device further includes a header in fluid communication with the outlet path, and a third antimicrobial filter, provided in the header. | 2021-10-28 |
20210330752 | FEED SUPPLEMENTS - Disclosed herein are embodiments of a combination and/or composition comprising a growth factor and one or more of silica, mineral clay, glucan, mannans, endoglucanohydrolase, yucca, quillaja, metal chelate, chromium compound, probiotic, polyphenol, direct fed microbial, copper species, vitamin, allicin, alliin, alliinase, yeast, growth promotant, preservative, antimicrobial, or vaccine. The growth factor may be an active growth factor such as an active insulin-like growth factor. Also disclosed are methods of administering the combination and/or composition to an animal. The combination and/or composition may provide a beneficial effect to the animal upon administration, such as, but not limited to, improved immune function, metabolism, milk production, growth, feed conversion, fertilization, reproduction, oocyte quality in a ruminant undergoing superovulation, embryo viability, muscle growth, muscle percentage, heart muscle development, egg product and/or quality, sperm production and/or quality, meat quality, or a combination thereof. | 2021-10-28 |
20210330753 | METHODS OF TREATING COVID-19 MEDIATED LUNG DAMAGE USING SURFACTANTS AND NATURAL ANTIBODIES - Disclosed is a method of treating respiratory viruses including coronaviruses such as SARS-CoV-2 using surfactant, surfactant protein A and/or surfactant protein D. The surfactant and surfactant protein treatment can be used in combination with immunoglobulin M administered intravenously. Surfactant proteins used in these embodiments, especially surfactant protein D, can be harvested from an exogenous source such as pigs, as they show improved resilience against viruses. | 2021-10-28 |
20210330754 | SELF-ASSEMBLING OXYGEN CARRIER COMPOSITIONS - Synthetic blood substitutes and methods for making them. A lipid-amphiphile blood-substitute precursor compound having a hydrophobic fatty acid/acyl moiety, a hydrophilic head moiety including a phosphate group, and a pH responsive moiety. The lipid-amphiphile precursor is configured to self-assemble from a solution mixture of phospholipid and cholesterol in the presence of hemoglobin and an allosteric effector into a hybrid-vesicle resulting from the combined self-assembly of both the amphiphilic lipid-oligomer and the lipids into an advanced vesicular structure containing a hemoglobin/allosteric effector payload. | 2021-10-28 |
20210330755 | HALOPEROXIDASE COMPOSITIONS AND USES THEREOF - A method of treating at least one of septicemia, endotoxemia or a bacterial infection in a subject can include administering to the subject a composition containing a therapeutically effective amount of a haloperoxidase. The haloperoxidase can be myeloperoxidase or eosinophil peroxidase. The haloperoxidase can inhibit lipopolysaccharide or Lipid A activity in the subject; as a non-limiting example, the haloperoxidase is not engaged in active haloperoxidase activity, but available for LPS or Lipid A binding and inhibition. | 2021-10-28 |
20210330756 | Acetylation of Miro1 - Deacetylation of rat Miro1 on Lysine 105 attenuates axon growth on non-permissive substrates by making mitochondria more sensitive to Ca levels, depolarizing mitochondrial membranes and blocking mitochondrial transport; the current disclosure provides an antibody that specifically recognizes the lysine 105 acetylated and not the deacetylated Miro1 protein. | 2021-10-28 |
20210330757 | METHODS AND COMPOSITIONS FOR INDUCING NEURAL PLASTICITY - A method of promoting compensatory plasticity of spared neural cells after a neural injury includes contacting the spared neural cells with an effective amount of a therapeutic agent comprising a therapeutic peptide, wherein the therapeutic peptide comprises an amino acid sequence with at least 70% identity to SEQ ID NO:32. | 2021-10-28 |
20210330758 | TREATMENT FOR BK POLYOMAVIRUS INFECTION - The present disclosure provides novel compositions and methods for treating infection by a viral pathogen, e.g., a BK or JC polyomavirus, using agents having sialidase activity. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by a pathogen. | 2021-10-28 |
20210330759 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM, ARDS, AND ACUTE LUNG INJURY USING BETA-GLUCOCEREBROSIDASE - The present invention relates to methods and compositions for treating a subject with a condition selected from: i) an on-going cytokine storm, ii) acute respiratory distress syndrome (ARDS), and/or iii) acute lung injury (ALI), using a composition comprising β-glucocerebrosidase, or a vector encoding β-glucocerebrosidase. In certain embodiments, the condition is caused by COVID-19 virus infection or other viral infection. | 2021-10-28 |
20210330760 | METHODS AND MATERIALS FOR TREATING OSTEOARTHRITIS - This document provides methods and materials for treating osteoarthritis. For example, a mammal having, or at risk for developing, osteoarthritis can be treated by increasing the level of one or more Klotho polypeptides (e.g., one or more alpha-Klotho (α-Klotho) polypeptides) within cells (e.g., chondrocytes) within the mammal. | 2021-10-28 |
20210330761 | PLASMINOGEN TREATMENT OF CONDITIONS ASSOCIATED WITH PAI-1 OVEREXPRESSION - The present invention concerns the use of plasminogen, a variant thereof, or an analog thereof having a plasminogen activity, for the prevention or treatment of a condition or a disease that is characterized with an increased PAI-1 level. The conditions and diseases that are characterized with an increased PAI-1 level, are regrouped within two categories: the diseases associated with an impaired vascular or tissue remodeling capacity, and the metabolic and hormonal disorders associated with an increased PAI-1 level. | 2021-10-28 |
20210330762 | MEDICAL APPLICATION OF MUTANT PLASMINOGEN AND PLASMIN POLYPEPTIDE THERAPEUTICS - Provided are methods for producing biologically active mutant recombinant plasminogen polypeptides with desired pharmaceutical properties. The refolded polypeptides may be treated with a plasminogen activator, such as tPA, urokinase, or streptokinase to generate biologically active mutant plasmin polypeptide for pharmaceutical use. Methods are also provided to producing biologically active fusion recombinant mutant plasminogen/plasmin polypeptides that can cross the BBB through receptor mediated transcytosis. The fusion partner may carry the mutant plasminogen/plasmin polypeptides into the brain for increased therapeutic efficiency. | 2021-10-28 |
20210330763 | MODIFIED FACTOR IX, AND COMPOSITIONS, METHODS AND USES FOR GENE TRANSFER TO CELLS, ORGANS, AND TISSUES - The invention relates to modified Factor IX coding sequence, expression cassette, vectors such as viral (e.g., lenti- or adeno-associated viral) vectors, and gene transfer methods and uses. In particular, to target Factor IX nucleic acid to cells, tissues or organs for expression (transcription) of Factor IX. | 2021-10-28 |
20210330764 | Collagenase Clostridium Histolyticum Injection Therapies - Collagenase Clostridium Histolyticum (EN3835) is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions. EN3835 targets the collagenase structural matrix at the site of injection and does not require systemic exposure. Embodiments include methods of lysing subdermal collagen to treat various conditions such as benign prostatic hyperplasia, tracheal stenosis, subglottic stenosis and scleroderma. | 2021-10-28 |
20210330765 | LIQUID NEUROTOXIN FORMULATION STABILIZED WITH TRYPTOPHAN OR TYROSINE - The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins. | 2021-10-28 |
20210330766 | Albumin-Free Botulinum Toxin Formulations - This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using such botulinum toxin formulations. | 2021-10-28 |
20210330767 | COMPOSITION FOR THE TREATMENT OF COVID-19 INFECTION, AND A METHOD OF TREATMENT - Oral composition and a method for the treatment of coronaviruses infections in humans and animals. The method includes the steps of administering orally a methionine cleaving-enzyme; administering orally or parentally a protease inhibitor; and orally administering pyridoxal-L-phosphate in a fluid. | 2021-10-28 |
20210330768 | METHODS OF TREATING FUNGAL INFECTIONS - This invention describes vaccine compositions and their methods of use utilizing inactivated fbp1Δ deletion mutant fungal cells. | 2021-10-28 |
20210330769 | UNIVERSAL ANTI-TAG CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AND METHODS OF TREATING CANCER - The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, αFITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of αFITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer. | 2021-10-28 |
20210330770 | Use of Car and Bite Technology Coupled with an SCFV from an Antibody Against Human Thymidine Kinase 1 to Specifically Target Tumors - Modified T-cells have paratopes against human TK1 epitopes, are made by producing monoclonal antibodies that are specific to TK1, creating chimeric antigen receptors (CARs) by fusion of the single-chain variable fragments (scFv) of the monoclonal antibodies to T-cell signalling domains, and transducing the CARs to the T-cells. | 2021-10-28 |
20210330771 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-10-28 |
20210330772 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-10-28 |
20210330773 | VACCINES AGAINST ANTIGENS INVOLVED IN THERAPY RESISTANCE AND METHODS OF USING SAME - Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent, such as a checkpoint inhibitor and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polypeptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided. | 2021-10-28 |
20210330774 | HERV-K-DERIVED ANTIGENS AS SHARED TUMOR ANTIGENS FOR ANTI-CANCER VACCINE - A composition or vaccine comprising at least one peptide, or an expression vector that induces expression of said at least one peptide in vivo, the peptide consisting of, or comprising, shared HERV-K derived antigens, and a pharmaceutically acceptable vehicle or excipient. Composition comprising Cytotoxic T Lymphocytes (CTLs) of a patient treated with such a peptide, or comprising T-cell Receptor (TCR) engineered T cells recognizing such a peptide. | 2021-10-28 |
20210330775 | VACCINE FOR PROTECTION AGAINST ETEC-INDUCED DIARRHEA COMPRISING DMLT - An oral vaccine for immunization against ETEC-induced diarrhea, comprising inactivated | 2021-10-28 |
20210330776 | PROTEINS AND IMMUNIZING COMPOSITIONS CONTAINING KLEBSIELLA PROTEINS AND METHODS OF USE - Provided herein are isolated proteins isolatable from a | 2021-10-28 |
20210330777 | ENHANCING IMMUNOGENICITY OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES - The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides from | 2021-10-28 |
20210330778 | ENHANCING IMMUNOGENICITY OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES - The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides from | 2021-10-28 |
20210330779 | METHOD FOR TREATING CERVICAL CANCER - A treatment of cervical tumor caused by human papillomavirus (HPV) infection is disclosed. Methods for improving cervical tumor treatment and methods for treating cervical tumor caused by HPV infection include administering a combination of a HPV-specific fusion protein and an immunomodulatory agent. | 2021-10-28 |
20210330780 | RECOMBINANT VECTOR FOR EXPRESSING VIRUS-LIKE PARTICLES IN PLANT AND METHOD FOR PREPARATION OF VACCINE COMPOSITION CONTAINING CIRCOVIRUS-LIKE PARTICLES BY USING SAME - The present invention relates to a technique of preparing a vaccine composition from PCV2 isolated from a plant transformed with a chlorophyll-targeting recombinant vector for expression in plants and provides a recombinant vector carrying a polynucleotide coding for a recombinant protein in which a chlorophyll-targeting protein and a PCV2 capsid protein are fused to each other. In addition, provided are a transgenic plant transformed with the recombinant vector, a method for isolating and purifying a target protein from the transgenic plant, a method for preparing a vaccine composition containing virus-like particles by using same, and a vaccine composition prepared by the preparation method. | 2021-10-28 |
20210330781 | INDUCE AND ENHANCE IMMUNE RESPONSES USING RECOMBINANT REPLICON SYSTEMS - The present disclosure generally relates to the use of different self-amplifying RNA molecules to enhance immune responses, for example immune responses following prophylactic vaccination or therapeutic administration. Some embodiments relate to compositions and methods for inducing an immune response in a subject using prime-boost immunization regimens. | 2021-10-28 |
20210330782 | GENETICALLY STABLE LIVE ATTENUATED RESPIRATORY SYNCYTIAL VIRUS VACCINE AND ITS PRODUCTION - Provided herein are recombinant respiratory syncytial viruses that contain mutations that make the disclosed viruses attractive vaccine candidates. The viruses disclosed contain attenuating mutations designed to have increased genetic and phenotypic stability. Desired combinations of these mutations can be made to achieve desired levels of attenation. Exemplary vaccine candidates are described. Also provided are polynucleotides capable of encoding the described viruses, as wells as methods for producing the viruses and methods of use. | 2021-10-28 |
20210330783 | HIV PRE-IMMUNIZATION AND IMMUNOTHERAPY - The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells. | 2021-10-28 |
20210330784 | VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND COMPOSITIONS AND METHODS OF USING THE SAME - Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed. | 2021-10-28 |
20210330785 | UNIVERSAL VACCINE PLATFORM - The disclosure relates to vaccination compositions, for example, against human papillomavirus, Zika virus, and flu virus. The disclosure also relates to vectors for producing the virus-like particles and immune complex platforms of the vaccination compositions. | 2021-10-28 |
20210330786 | COMPOSITIONS COMPRISING BACTERIAL STRAINS - The invention provides a composition comprising a bacterial strain for use in stimulating the immune system in a subject. | 2021-10-28 |
20210330787 | Antigen Binding Proteins That Bind PD-L1 - There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers. | 2021-10-28 |
20210330788 | USES OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS - The invention provides uses of anti-B cell maturation antigen (BCMA) chimeric antigen receptors (CARs) for treating B-cell related conditions, such as BCMA-expressing cancers. | 2021-10-28 |
20210330789 | ADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER - Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab. | 2021-10-28 |
20210330790 | Method for Treating Vitiligo Based on Enhancing the Alternative Cellular Energy Pathway Using KELEA Activated Water - Water can either naturally contain or can be made to contain an added level of an environmental force called KELEA, an abbreviation for Kinetic Energy Limiting Electrostatic Attraction. Placing KELEA activated water directly onto the area of skin with vitiligo leads to re-pigmentation of the affected area of skin. The therapy is attributed to enhancing the body's alternative cellular energy (ACE) pathway. This pathway has an anti-inflammatory effect and also a regenerative effect referred to as REACH, an abbreviation for Regenerative Energy Assisted Clinical Healing. The restoring of melanocyte in patients with vitiligo will likely apply to other illnesses in which there is melanocyte degeneration, including Parkinson's disease. Enhancing the ACE pathway using KELEA-activated water is also applicable to other illnesses classified as being autoimmune. The KELEA activated water can also be used in wearable waterceutical pouches. | 2021-10-28 |
20210330791 | MULTIMODAL THERAPY FOR CANCER CELL DESTRUCTION - The field of the disclosure relates generally to cancer cell destruction and, more specifically, to cancer cell destruction by photo-magnetic irradiation mediated multimodal therapy using smart nanostructures. | 2021-10-28 |
20210330792 | (BACTERIO)CHLOROPHYLL PHOTOSENSITIZERS FOR TREATMENT OF EYE DISEASES AND DISORDERS - An ophthalmic composition is provided, comprising chlorophyll or bacteriochlorophyll compounds for photodynamic treatment (PDT) of diseases, disorders and conditions associated with corneal or scleral anomalies, such as corneal thinning and scleral stretching. | 2021-10-28 |
20210330793 | METHODS AND COMPOSITIONS FOR SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT - An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage. | 2021-10-28 |
20210330794 | EXTERNAL PREPARATION COMPRISING NON-LAMELLAR LIQUID CRYSTAL-FORMING LIPID - The present invention relates to an external preparation that is well retained on a living body surface and is capable of increasing drug permeability, in particular, an external preparation comprising a non-lamellar liquid crystal-forming lipid and a drug. | 2021-10-28 |
20210330795 | COMPOSITIONS COMPRISING TRI- AND PENTA-BLOCK SYNTHETIC COPOLYPEPTIDE HYDROGELS - Disclosed herein are mixtures of triblock or pentablock copolypeptide hydrogels (DCH). These hydrogels possess improved mechanical properties, such as elasticity, that are synergistically increased over the individual component DCHs, to greater than would be expected for a linear combination of the components. Also disclosed herein are methods of making and using the triblock and pentablock copolypeptide hydrogels. | 2021-10-28 |
20210330796 | LONG-ACTING POLYMERIC DELIVERY SYSTEMS - Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural). | 2021-10-28 |
20210330797 | STABLE CANNABINOID FORMULATIONS - The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use. | 2021-10-28 |
20210330798 | TREATMENT OF INFECTIONS - The present invention relates among other aspects to a conjugate or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said conjugate or its pharmaceutically acceptable salt for use in a method of preventing or treating an infection, wherein said conjugate is water-insoluble and comprises a polymeric moiety —Z to which a plurality of moieties -L | 2021-10-28 |
20210330799 | POLYSACCHARIDE AND METHODS - There is provided a molecule comprising a chain of seven or more contiguous units of 4,6-dideoxy-4-acylamido-α-pyranose each pair of units joined by a C | 2021-10-28 |
20210330800 | ALBUMIN BINDING PEPTIDE CONJUGATES AND METHODS THEREOF - The present invention provides a conjugate comprising an albumin binding peptide and a cargo, compositions for directing cargos to the lymphatic system, and vaccines. The methods of the invention can be used to increase an immune response, or to treat cancer or an infectious disease. | 2021-10-28 |
20210330801 | NOVEL PROTEIN DRUG CONJUGATE FORMULATION - The invention provides stable pharmaceutical formulation comprising a protein drug conjugate along with one or more suitable excipient(s) such that the formulation is devoid of any buffer components and methods of making the same. The protein drug conjugate according to the present invention is antibody drug conjugate, preferably trastuzumab maytansinoid conjugate. Suitable excipient(s) according to the present invention is selected from suitable bulking agents, suitable tonicity modifiers, suitable stabilizers and the like. | 2021-10-28 |
20210330802 | METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE - The present invention provides a method for producing an antibody-drug conjugate (ADC) comprising an antibody and a drug linked to each other via a linker. The present invention provides a method for producing, for example, an antibody-drug conjugate (ADC) comprising an antibody and a drug linked to each other via a linker, or a pharmaceutical comprising the ADC, the method comprising mixing, using a microreactor, a solution comprising tricarboxyethyl phosphine (TCEP) and an IgG antibody under reduction reaction with TCEP, with a solution comprising a stoichiometrically excessive amount of an inhibitor of TCEP based on TCEP. | 2021-10-28 |
20210330803 | PROTEIN-ANTIVIRAL COMPOUND CONJUGATES - Provided herein are compounds, compositions, and methods for the treatment of diseases and disorders associated with influenza, including VX-787 and derivatives thereof, baloxavir and derivatives thereof, and baloxavir marboxil and derivatives thereof, and protein (e.g., antibody) drug conjugates thereof. | 2021-10-28 |
20210330804 | CELL PENETRATING CONJUGATES AND METHODS OF USE THEREOF - Provided herein are cell penetrating conjugates. The conjugates include a non-cell penetrating protein attached to a phosphorothioate nucleic acid or phosphorothioate polymer backbone, wherein the phosphorothioate nucleic acid or phosphorothioate polymer backbone enhances intracellular delivery of the non-cell penetrating protein. Also provided are compositions and kits comprising the cojugates. | 2021-10-28 |
20210330805 | N-ACETYLGALACTOSAMINO DENDRON-CLEARING AGENT FOR DOTA-PRETARGETED RADIOIMMUNOTHERAPY - The present disclosure provides compositions and methods for the treatment of cancer. Specifically, the compositions of the present technology include novel clearing agents that may be used in pretargeted radioimmunotherapy. | 2021-10-28 |
20210330806 | METHODS AND COMPOSITIONS INHIBITING ENVELOPED VIRUSES USING HIGH MOLECULAR WEIGHT HYDROPHOBICALLY MODIFIED ALKALI SWELLABLE EMULSION POLYMERS - This invention relates to methods and compositions for inhibiting the transmission of enveloped viruses, which entails applying a composition containing a high molecular weight hydrophobically-modified polymer to an infectable or ingestible surface that may contain viruses and wherein said anti-viral composition is substantially free of surfactant having an HLB greater than about 12. | 2021-10-28 |
20210330807 | NOVEL HYDROGEL CONJUGATES - The present invention relates to conjugates comprising backbone moieties that are crosslinked via particular crosslinker moieties to which a plurality of drug moieties are covalently and reversibly conjugated. It also relates to their use as medicaments and their use in the diagnosis, prevention and treatment of diseases. | 2021-10-28 |
20210330808 | SMALL POLYMERIC CARRIERS FOR DELIVERY OF AGENTS - A polymer includes a hydrophobic polymer backbone, a first plurality of pendant groups attached to the hydrophobic polymer backbone and including at least one group including a plurality of hydroxyl groups, and a second plurality of pendant groups attached to the hydrophobic polymer backbone and comprising at least one hydrophilic polymer. | 2021-10-28 |
20210330809 | LIPID-COATED PARTICLES FOR TREATING VIRAL INFECTIONS - The present invention relates to lipid-coated particles for treating viral infections, including viral encephalitis infections. In particular, an antiviral compound can be disposed within the lipid-coated particle, thereby providing an antiviral carrier. Methods of making and using such carriers are described herein. | 2021-10-28 |
20210330810 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY - The invention provides compositions containing cargo molecules attached to elements that improve the function of the cargo molecules in the body of a subject. The compositions are useful for therapeutic and diagnostic purposes. Furthermore, the invention outlines ways in which these compositions can be produced; the core molecule can be functionalized, via bioorthogonal click chemistry, in such a way as to impart modular characteristics. This functionalization simultaneously allows for loading of biologically relevant cargo and provides stabilization to the overall structure of the molecule. | 2021-10-28 |
20210330811 | OPTIMIZED AGA GENES AND EXPRESSION CASSETTES AND THEIR USE - This invention relates to polynucleotides comprising optimized aspartylglucosaminidase (AGA) open reading frames and vectors and cells comprising the same. The invention further relates to methods of using the same for delivery of the open reading frame to a cell or a subject and methods for treating aspartylglucosaminuria (AGU) in a subject. | 2021-10-28 |
20210330812 | TREATMENT OF RETINAL DEGENERATION USING GENE THERAPY - The present invention relates to an improved method of providing photoreceptor function to a cell, for example for use in the treatment of retinal degeneration. The present invention also relates to compositions and kits, in particular for use in such methods. | 2021-10-28 |
20210330813 | RNAI INDUCED C9ORF72 SUPPRESSION FOR THE TREATMENT OF ALS/FTD - The present invention provides for specific target RNA sequences that can in particular be applied in RNAi based gene therapy approaches for the treatment of ALS and/or FTD. These specific target RNA sequences were found by selecting target RNA sequences that were conserved in the C9ORF72 target RNA sequence and were shown to provide for efficient silencing. Also are provided combinations of target RNA sequences that are useful in the treatment of ALS and/or FTD. | 2021-10-28 |
20210330814 | METHODS OF TREATING NON-SYNDROMIC SENSORINEURAL HEARING LOSS - Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of a stereocilin protein, and the use of these compositions to treat non-syndromic sensorineural hearing loss in a subject. | 2021-10-28 |
20210330815 | AAV VECTOR FOR TREATMENT OF FRIEDREICH'S ATAXIA - Provided herein are nucleic acids, recombinant adeno-associated viral particles, compositions and methods related to treating Friedreich's ataxia. In some examples, the nucleic acids, recombinant adeno-associated viral particles, compositions and methods involve us of a FXN coding sequence, a truncated FXN 3′ UTR, and a prompter. | 2021-10-28 |
20210330816 | GENE THERAPY FOR OCULAR DISORDERS - Compositions and methods are provided for treating ocular disorders in a subject are provided. In one aspect, an adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding CNGA3. In another aspect, an adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding CNGB3. In another aspect, an adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding REP-1. In desired embodiments, the subject is human, cat, dog, sheep, or non-human primate. | 2021-10-28 |
20210330817 | SYNTHETIC DNA VECTORS AND METHODS OF USE - Provided herein are isolated DNA vectors comprising a heterologous gene, wherein the DNA vector is devoid of bacterial plasmid DNA and/or bacterial signatures, which can abrogate persistence in vivo. The invention also features pharmaceutical compositions (non-immunogenic pharmaceutical compositions) including the DNA vectors of the invention, which can be used for induction of long-term, episomal expression of a heterologous gene in a subject. The invention involves methods of treating a subject by administering the DNA vectors of the invention, including methods of treating disorders associated with a defect in a target gene. | 2021-10-28 |
20210330818 | METHOD FOR ANALYZING NON-OBSERVED EFFECT CONCENTRATION (NOEC) OF CHEMICAL ON ORGANISM - The present invention provides a method for analyzing the non-observed effect concentration (NOEC) of a chemical on an organism. The analysis method includes the following steps: 1) conducting a chronic toxicity test on a test organism with a test chemical at different concentrations, and conducting assays to obtain several sets of endpoint effect data; 2) classifying the several sets of endpoint effect data obtained in step 1); and 3) constructing hypothesis testing models with the data classified in step 2), and according to the statistical significance values from hypothesis testing models, among the same set of endpoint effect data, adopting the highest concentration of the test chemical that do not produce a significant effect as NOEC within the set; and among the different sets of endpoint effect data, adopting NOEC of the set with the smallest NOEC value as NOEC of the test chemical on the test organism. | 2021-10-28 |
20210330819 | DESIGN AND DEVELOPMENT OF NEUROKININ-1 RECEPTOR-BINDING AGENT DELIVERY CONJUGATES - Neurokinin-1 (NK-1) receptor-binding agent delivery conjugates, compositions comprising NK-1 receptor-binding agent delivery conjugates, and methods for making and administering NK-1 receptor-binding agent delivery conjugates are provided. A conjugate may include an NK-1 receptor-binding moiety, a tinker group containing at least one linker selected from the group of a releasable linker and a spacer linker, and an active agent linked to the linker group. The active agent may be selected from the group of fluorophore-containing compounds, radionuclide-containing compounds, and therapeutic agents for treatment of tumor cells characterized by over-expression of the NK-1 receptor. | 2021-10-28 |
20210330820 | NANOEMULSION OF IODINATED FATTY ACIDS FOR CT IMAGING - An iodinated CT contrast agent made of fatty acid derivatives for non-invasive visualisation and quantification of the brown and/or beige adipose tissue (BAT) or for imaging the heart and/or liver of a subject, to be taken orally which is a breakthrough in CT imaging. Image resolution by CT is significantly enhanced compared to PET. | 2021-10-28 |
20210330821 | METHODS OF MAKING PROSTATE CANCER TREATMENT DECISIONS - Provided herein are methods for assessing a subject with prostate cancer. The methods are also directed to or may further comprise treating the subject and/or making treatment management decisions based on the assessing. | 2021-10-28 |
20210330822 | FLUORESCENT PROBE FOR CYCLOOXYGENASE-2 - Cyclooxygenase-2 (COX-2) over-expression is prominent in inflammatory diseases, neurodegenerative disorders, and cancer. Directly monitoring COX-2 activity within its native environment poses an exciting approach to account for and illuminate the effect of the local environments on protein activity. Herein, we report the development of CoxFluor, the first activity-based sensing approach for monitoring COX-2 within live cells with confocal microscopy and flow cytometry. CoxFluor strategically links a natural substrate with a dye precursor to engage both the cyclooxygenase and peroxidase activities of COX-2. This catalyzes the release of resorufin and the natural product, as supported by molecular dynamics and ensemble docking. CoxFluor enabled the detection of oxygen-dependent changes in COX-2 activity that are independent of protein expression within live macrophage cells. | 2021-10-28 |
20210330823 | Methods for Cell Labeling and Medical Imaging - Methods of ex vivo labeling of a biological material for in vivo imaging, methods of labeling a biological material in vivo, methods for preparing a labeling agent, and methods for in vivo imaging of a subject using a biological material labeled with a labeling agent are disclosed. In one non-limiting example, the biological material is selected from cells and the labeling agent is a | 2021-10-28 |